Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 5/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820208 | 0.80 | — | — | |
| SCHEMBL44910 | 0.79 | PTGS1 (0.31) | APEX1PTGS1AKR1C3 | |
| SCHEMBL3916360 | 0.79 | PTGS1 (0.31) | APEX1PTGS1AKR1C3 | |
| Acetic Acid SCHEMBL6238307 | 0.77 | FFAR3 (0.32) | PTGS1AKR1C3 | |
| Bromide SCHEMBL1061718 | 0.77 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| Chloromethane SCHEMBL219839 | 0.77 | TUBB1 (0.31) | PTGS1AKR1C3 | |
| Hydrochloric Acid SCHEMBL5177431 | 0.77 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| Sulfuric Acid SCHEMBL10795309 | 0.77 | APEX1 (0.30) | APEX1 | |
| SCHEMBL6280583 | 0.77 | APEX1 (0.30) | APEX1 | |
| Hydrochloric Acid SCHEMBL10569862 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951216-B1 | ANTI-MICROBIAL POLYMER | FACHHOCHSCHULE MUENSTER (DE) | 2018-07-18 | — | — | EP | claimed |
| US-7820753-B2 | Block copolymers | BIOCOMPATIBLES UK LIMITED (GB) | 2010-10-26 | — | — | US | claimed |
| US-20070113353-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY | 2007-05-24 | — | — | US | claimed |
| US-20240108720-A1 | SOLE USE OF POLYMERSOME ASSOCIATED ADJUVANT FOR STIMULATING AN IMMUNE RESPONSE | ACM BIOLABS PTE LTD (SG) | 2024-04-04 | — | — | US | disclosed |
| EP-4322922-A1 | POLYMERSOMES COMPRISING A SOLUBLE ENCAPSULATED POLYNUCLEOTIDE AND AN IONIZABLE LIPID AS WELL AS METHODS OF MAKING AND USES THEREOF | ACM Biolabs Pte Ltd (SG) | 2024-02-21 | — | — | EP | disclosed |
| US-20230398207-A1 | MODULATING TH1/TH2 IMMUNE RESPONSE BY ADMINISTERING TWO POPULATIONS OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN AND AN ASSOCIATED ADJUVANT | ACM BIOLABS PTE LTD (SG) | 2023-12-14 | — | — | US | disclosed |
| EP-4288033-A1 | SOLE USE OF POLYMERSOME ASSOCIATED ADJUVANT FOR STIMULATING AN IMMUNE RESPONSE | ACM Biolabs Pte Ltd (SG) | 2023-12-13 | — | — | EP | disclosed |
| EP-4259197-A1 | MODULATING TH1/TH2 IMMUNE RESPONSE BY ADMINISTERING TWO POPULATIONS OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN AND AN ASSOCIATED ADJUVANT | ACM Biolabs Pte Ltd (SG) | 2023-10-18 | — | — | EP | disclosed |
| US-20230256082-A1 | VACCINE AGAINST HUMAN-PATHOGENIC CORONAVIRUSES | ACM BIOLABS PTE LTD (SG) | 2023-08-17 | — | — | US | disclosed |
| EP-4138899-A2 | VACCINE AGAINST HUMAN-PATHOGENIC CORONAVIRUSES | ACM Biolabs Pte Ltd (SG) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022123070-A1 | MODULATING TH1/TH2 IMMUNE RESPONSE BY ADMINISTERING TWO POPULATIONS OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN AND AN ASSOCIATED ADJUVANT | ACM BIOLABS PTE LTD (SG) | 2022-06-16 | — | — | WO | disclosed |
| US-6451495-B1 | Toner and developer compositions with charge enhancing additives | XEROX CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-6426170-B1 | Toner and developer compositions with charge enhancing additives | XEROX CORPORATION | 2002-07-30 | — | — | US | disclosed |
| US-6004712-A | CORE AND THEREOVER A POLYMER OF (1) METHYLMETHACRYLATE AND A MONOALKYL AMINOALKYL METHACRYLATE, OR (2) A POLYMER OF METHYLMETHACRYLATE AND DIALKYLAMINOALKYL METHACRYLATE, TONER AND DEVELOPER | XEROX CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5728340-A | SURGICAL GLOVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-03-17 | — | — | US | disclosed |
| US-5391343-A | Forming polyetherurethane by reacting homo or copolymer of polyetherdiol and methylenebis/4-phynylisocyanate/, then chain extending diamine to forming polyetherurethaneurea; degassing, dipping,coating, removal, drying; surgical gloves | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0343985-B1 | Spandex fiber with copolymer soft segment | DU PONT (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5000899-A | Polyetherurethane copolymers chain extended with diamines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| US-4895927-A | Water soluble, self-crosslinking, polymeric condensation product of amino (meth) acrylate and phosponic acid ester | CIBA-GEIGY CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0343985-A2 | Spandex fiber with copolymer soft segment | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398207-A1 | MODULATING TH1/TH2 IMMUNE RESPONSE BY ADMINISTERING TWO POPULATIONS OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN AND AN ASSOCIATED ADJUVANT | IL2, IFNG, CD69 | APEX1 4088/4885PTGS1 256/4885AKR1C3 2881/4885 |
| US-20240108720-A1 | SOLE USE OF POLYMERSOME ASSOCIATED ADJUVANT FOR STIMULATING AN IMMUNE RESPONSE | MYD88, TLR3, TLR6 | APEX1 1826/4885PTGS1 815/4885AKR1C3 4603/4885 |
| US-20230256082-A1 | VACCINE AGAINST HUMAN-PATHOGENIC CORONAVIRUSES | CD14, SARS1, ACE2 | APEX1 4259/4885PTGS1 1389/4885AKR1C3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.